Forum Topics TLX TLX ASX Announcements

Pinned straw:

Added 2 months ago

Another significant step in $TLX's integrated strategy, this time acquiring the US network of RLS Group Ltd network of 31 licensed radiopharmacies covering 85% of the US population,

ASX Announcement

Deal comprises "upfront cash consideration of US$230 million before adjustments for cash and cash equivalents (net of restricted cash); debt and debt equivalents; transaction expenses; and working capital, and deferred cash consideration up to a maximum of US$20 million, contingent on achievement of certain milestones related to demonstration of accretive financial and operational performance during the four-quarters following closing. The acquisition and related transaction costs are expected to be funded from existing cash reserves."

RLS already distirbutes Illuccix and will continue to operate as an independent business unit, servong both $TLX and "select strategic commercial partners".

RLS is a significant business in its own right, earning 2023 revenues of $US158m in the rapidly emerging and increasingly material area of radiopharmaceuticals.

I have no way of fundamentally valuing this deal, however, it is consistent with $TLX strategy of ensuring it controls its own supply chain. Increasingly, however, i'ts looking like $TLX will be an important player in the supply chains of others, and it will be interesting to see if this attracts any regualtory interest. Perhaps not yet, but something to keep an eye on.

Disc: Held in RL and SM

Remorhaz
Added 2 months ago

Very interesting @mikebrisy - UBS (who cover TLX - Buy 12m PT $29) havn't said much yet - their first take just says "Company had repeatedly telegraphed intent to do deals to enhance supply chain integration. This will provide scale-up for isotope production and finished product delivery. We understand no impact to CAH distribution relationship and benefit to gm". Hopefully they'll follow up with something/more detailed analysis in the coming days?

DISC: Held in RL & SM


14

mikebrisy
Added 2 months ago

@Remorhaz I hope $TLX will provide some insights into the economics of the acquired business in due course, as the revenues are material compared with $TLX today.

I’m not too concerned for now as more of the value depends on the progress of approvals of the 2 next diagnostic products. And of course clinical development of the therapeutics.

I imagine this could be a very smart move.

$CSL’s Behring business has shown how valuable a vertically integrated model can be when the supply chain is not commoditised. I suspect radiopharmacy - -while of course entirely different - offers the potential for significant benefits from being vertically integrated. Precise control of timing for the last mile is huge in this supply chain!

My triggers to build my position, however, rest on the product portfolio’s progression. And that’s because I can’t quantify just how critical the integrated model is here.

18